MorphoSys AG has announced the publication of three MorphoSys abstracts which were submitted to the 20th Congress of the European Hematology Association (EHA) to take place from June 11 - 14 in Vienna, Austria.
The abstracts include pre-clinical and clinical data on the Company's proprietary drug candidate MOR202 from a Phase 1/2a study in patients with multiple myeloma and updated clinical data for the MOR208 program.
"The progress of our cancer compounds MOR202 and MOR208 is increasingly gaining visibility," commented Dr. Arndt Schottelius, Chief Development Officer of MorphoSys AG. "We are looking forward to presenting our most advanced cancer programs at the EHA congress, including efficacy data for MOR202 from the Phase 1/2a study in multiple myeloma."
List of abstracts:
A phase 1/2a study of the human anti-CD38 antibody MOR202 (MOR03087) in relapsed or refractory multiple myeloma
The presentation will include the in the abstract described safety results and additional first efficacy results. The oral presentation will take place on Sunday, June 14, 09:00 - 09:15 am CEST.
Effect of IMiD compounds on CD38 expression on multiple myeloma cells: MOR202, a human CD38 antibody in combination with pomalidomide.
The poster presentation will take place on Saturday, June 13, 5:15 - 6:45 pm CEST.
A phase 2a study of single-agent MOR208, an Fc-optimized anti-CD19 antibody, in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).
The abstract will be on display on the e-poster screens from Friday, June 12, 09:30 am to Saturday, June 13, 6:45 pm CEST.